Formulation and Design of Biopharmaceuticals for the Treatment of Autoimmune Diseases
American Journal of Pharmaceutics · 2025-02-28 · 6 (1) · 11-20
DOI: 10.71465/ajph2735 ↗At a glance
Journal article in American Journal of Pharmaceutics, published online on 2025-02-28. Written by Dr. Nida Imran. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Autoimmune diseases represent a group of conditions where the immune system mistakenly attacks the body’s own cells. Biopharmaceuticals have emerged as a promising class of therapeutic agents for treating these diseases by targeting specific components of the immune system. This article discusses the formulation and design of biopharmaceuticals, including monoclonal antibodies, cytokine inhibitors, and other biologics, for the treatment of autoimmune disorders. The mechanisms of action, challenges in formulation, and regulatory considerations are explored. Additionally, the article highlights the advancements in personalized medicine, which aim to optimize biopharmaceutical therapies based on individual patient profiles.
Cite
APA
Imran, D. N. (2025). Formulation and Design of Biopharmaceuticals for the Treatment of Autoimmune Diseases. American Journal of Pharmaceutics, 6(1), 11-20. https://doi.org/10.71465/ajph2735
Vancouver
Imran DN. Formulation and Design of Biopharmaceuticals for the Treatment of Autoimmune Diseases. American Journal of Pharmaceutics. 2025;6(1):11-20. doi:10.71465/ajph2735
BibTeX
@article{Imran2025,
author = {Imran, Dr. Nida},
title = {Formulation and Design of Biopharmaceuticals for the Treatment of Autoimmune Diseases},
journal = {American Journal of Pharmaceutics},
year = {2025},
volume = {6},
number = {1},
pages = {11--20},
doi = {10.71465/ajph2735}
}
EUVIMED